BioMarin Pharmaceutical Inc. — Q1 2024 Form 10-Q
Business context and period: Global biotechnology company focused on therapies for rare genetic diseases. This summary covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Amounts below are in U.S. dollars.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Total revenue | $648.8 million | $596.4 million |
| Net product revenue | $637.8 million | $586.4 million |
| Operating income | $88.5 million | $62.4 million |
| Net income | $88.7 million | $50.9 million |
| Diluted EPS | $0.46 | $0.27 |
| Gross margin | 80.7% | 77.3% |
| Operating cash flow | $47.0 million | $(73.9) million |
| Cash, cash equivalents and investments | $1.667 billion | $1.685 billion at Dec. 31, 2023 |
| Convertible debt, net carrying value | $1.088 billion | $1.087 billion at Dec. 31, 2023 |
Operating margin was approximately 13.6% versus 10.5%; net margin was approximately 13.7% versus 8.5%. Cash and cash equivalents were $747.0 million, short-term investments $299.6 million, and long-term investments $620.6 million at quarter-end. Current assets were $2.985 billion and current liabilities $1.088 billion. The company said available cash, product-generated cash and short-term investments should meet liquidity needs for at least 12 months.
Material changes and operating drivers
- Revenue increased $52.4 million, led by VOXZOGO, up $65.1 million to $152.9 million, and PALYNZIQ, up $13.3 million to $75.7 million. VIMIZIM rose $3.4 million to $192.6 million.
- NAGLAZYME declined $17.4 million to $105.6 million, mainly due to timing of large government orders; KUVAN declined $14.6 million to $35.9 million amid generic competition.
- Research and development expense rose $33.2 million to $205.0 million, primarily due to early-pipeline and preclinical work. SG&A rose $14.9 million to $225.9 million, including higher G&A, employee, legal and consulting costs.
- Cost of sales fell $10.3 million to $125.2 million. Management attributed improved gross margin chiefly to lower per-unit manufacturing costs, lower third-party royalties and a favorable product mix.
- Q1 2024 included a $10.0 million gain from a third party’s regulatory milestone related to previously sold intangible assets. Q1 2023 included a $12.6 million impairment of a non-marketable equity investment, contributing to the year-over-year improvement in other income (expense).
- Operating cash flow improved by $120.9 million, which management primarily attributed to the timing of customer receipts, partly offset by vendor-payment timing. Cash declined $8.1 million during the quarter.
Outlook, risks and contingencies
- Management expects gross margin to increase modestly compared with 2023, supported by a mix shift toward higher-margin products. It expects R&D and SG&A expenses to increase in future periods. Interest income is expected to rise moderately over the next 12 months; interest expense is expected to decline following settlement of the notes due in August 2024. The filing does not provide a clear full-year revenue or earnings guidance figure.
- VOXZOGO demand has exceeded projections in some markets. Management expects supply constraints through the first half of 2024, potentially modestly reducing revenue growth and delaying market launches or development activities. It is working to increase fill-finish capacity and said it expects no material revenue impact if manufacturing plans are executed successfully.
- Management completed an R&D portfolio assessment: some programs will be accelerated and others discontinued; none were discontinued due to safety signals. The filing does not quantify the programs or expected financial effects.
- $495 million principal amount of 0.599% convertible notes matures in August 2024; $600 million of 1.25% notes matures in May 2027. If the 2024 notes are not converted, they must be repaid in cash. The company expects cash settlement if its share price remains below the approximately $124.67 conversion price.
- Purchase commitments were estimated at $386.7 million, including $340.6 million expected to be paid during the remainder of 2024. Reasonably possible contingent milestone payments totaled $738.6 million, of which up to $16.4 million could be payable in the next year if conditions are met.
- The company received a DOJ subpoena seeking documents about sponsored testing programs for VIMIZIM and NAGLAZYME, has produced documents and is cooperating. It cannot assess the investigation’s outcome or potential impact.
- Other risks include reimbursement and pricing pressure, KUVAN generic erosion, foreign-exchange exposure, reliance on international markets and periodic government orders, manufacturing and supply constraints, and regulatory and clinical-development uncertainty. Two customers represented 25% of Q1 product revenue combined.
Presentation of foreign-currency remeasurement gains and losses and idle plant costs changed in Q1 2024; prior-period figures were revised for comparability. The change did not affect prior-period net income, equity or EPS. Disclosure controls were deemed effective at March 31, 2024.
Important facts for investors to verify
- Whether VOXZOGO supply increases as planned and how the constraint affects 2024 sales and market expansion.
- Repayment or conversion outcome for the $495 million notes due August 2024, and the cash impact.
- Progress and financial implications of the R&D portfolio changes and expected increases in R&D and SG&A.
- Developments in the DOJ inquiry, including any potential consequences for the company.
- Trends in KUVAN generic competition, government-order timing, customer collections and currency effects.